Surrozen, Inc. SRZN
31.67 USD -0.21 (-0.66%)
At closeNov 12, 2026, 4:00 PM EST
31.67 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
30.53 Day range 32.45
12.12 52-week range 37.83
- YTD
- +40.13%
- 1 year
- +144.74%
News
benzinga.com Guggenheim Maintains Buy on Surrozen, Raises Price Target to $80 Guggenheim analyst Yatin Suneja maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $42 to $80.
benzinga.com Cantor Fitzgerald Maintains Overweight on Surrozen, Raises Price Target to $62 Cantor Fitzgerald analyst Steve Seedhouse maintains Surrozen (NASDAQ:SRZN) with a Overweight and raises the price target from $40 to $62.
globenewswire.com Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a…
globenewswire.com Surrozen to Present at Upcoming Healthcare Investor Conference SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the…
globenewswire.com Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power…
defenseworld.net Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD) Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Surrozen (NASDAQ: SRZN - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two…
defenseworld.net Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial Comparison Surrozen (NASDAQ: SRZN - Get Free Report) and Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two…
globenewswire.com Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross…
benzinga.com Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; several other stocks also fell premarket.
benzinga.com HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54 HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $44 to $54.
benzinga.com Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen…
benzinga.com Crude Oil Rises Over 4%; Darden Earnings Miss Views U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
benzinga.com Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy Surrozen Inc. (NASDAQ:SRZN) skyrocketed on Thursday after the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate SZN-8141 for treating…
benzinga.com Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy Surrozen submitted an IND application to the FDA for SZN-8141 to treat diabetic macular edema, with trial data expected in late 2027.
benzinga.com Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000 U.S. stocks fell Thursday as tech slid; jobless claims beat estimates. Oil rose, while APUS surged 245% and BENF plunged 33%.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to…
seekingalpha.com Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in…
globenewswire.com Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power…
globenewswire.com Surrozen to Present at Upcoming Healthcare Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the…
benzinga.com HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $44 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and maintains $44 price target.
globenewswire.com Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data…
marketbeat.com Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright Surrozen NASDAQ: SRZN Chief Executive Officer Craig Parker outlined the company's rationale for developing Wnt-targeting retinal disease therapies during H.C. Wainwright's 6th Annual Ophthalmology…
globenewswire.com Surrozen to Present at Upcoming Healthcare Investor Conference SOUTH SAN FRANCISCO, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the…
globenewswire.com Surrozen to Present at Upcoming Healthcare Investor Conference SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the…- benzinga.com HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $44 HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $36 to $44.
benzinga.com Earnings Scheduled For May 6, 2026 
globenewswire.com Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH…
globenewswire.com Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the…
defenseworld.net Head-To-Head Review: Surrozen (NASDAQ:SRZN) & MediWound (NASDAQ:MDWD) Surrozen (NASDAQ: SRZN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies…
zacks.com Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains? Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase…
defenseworld.net Tcg Crossover Gp Ii, Llc Acquires 106,658 Shares of Surrozen (NASDAQ:SRZN) Stock Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the firm's stock in a transaction that occurred on Tuesday, March 24th. The…- benzinga.com HC Wainwright & Co. Reiterates Buy on Surrozen, Raises Price Target to $36 HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $32 to $36.
- benzinga.com Surrozen Q4 EPS $(20.13) Misses $(1.08) Estimate, Sales $500.000K Inline Surrozen (NASDAQ:SRZN) reported quarterly losses of $(20.13) per share which missed the analyst consensus estimate of $(1.08) by 1755.3 percent. This is a 133.53 percent decrease over losses of…
- benzinga.com Cantor Fitzgerald Initiates Coverage On Surrozen with Overweight Rating, Announces Price Target of $40 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Surrozen (NASDAQ:SRZN) with a Overweight rating and announces Price Target of $40.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Surrozen Q3 EPS $(8.36) Misses $(1.14) Estimate, Sales $983.000K Down From $10.000M YoY Surrozen (NASDAQ:SRZN) reported quarterly losses of $(8.36) per share which missed the analyst consensus estimate of $(1.14) by 636.56 percent. This is a 1800 percent decrease over losses of $(0.44)…- benzinga.com Surrozen Announces Termination Of Collaboration Agreement With TCGFB, Effective November 13, 2025; No Side To Incur Any Termination Penalties On October 14, 2025, Surrozen, Inc. (the "Company") received notice from TCGFB, Inc. ("TCGFB") that TCGFB has elected to terminate the Collaboration Agreement (the "Collaboration Agreement") between…
- benzinga.com Surrozen Q2 EPS $2.55 Beats $(1.11) Estimate, Sales $983.000K Surrozen (NASDAQ:SRZN) reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $(1.11) by 329.73 percent. This is a 131.91 percent increase over losses of $(7.99)…
benzinga.com This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results.
benzinga.com Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results.- benzinga.com Earnings Scheduled For March 22, 2023 Companies Reporting Before The Bell • Boyd Gaming (NYSE:BYD) is estimated to report quarterly earnings at $1.09 per share on revenue of $848.27 million.
- benzinga.com Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C.
benzinga.com Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who…- benzinga.com Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with…
- benzinga.com Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM ImmunoTech recently reported safety, tolerability and biological activity data for intranasal ampligen in…